GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Total Assets

Novelion Therapeutics (STU:QLTA) Total Assets : €302.8 Mil (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics Total Assets?

Novelion Therapeutics's Total Assets for the quarter that ended in Mar. 2019 was €302.8 Mil.

Total Assets is connected with ROA %. Novelion Therapeutics's annualized ROA % for the quarter that ended in Mar. 2019 was -37.38%. Total Assets is also linked to Revenue through Asset Turnover. Novelion Therapeutics's Asset Turnover for the quarter that ended in Mar. 2019 was 0.09.

Novelion Therapeutics Total Assets Historical Data

The historical data trend for Novelion Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Total Assets Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.06 133.26 455.78 312.08 300.37

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 290.72 291.32 278.51 300.37 302.78

Novelion Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Novelion Therapeutics's Total Assets for the fiscal year that ended in Dec. 2018 is calculated as

Total Assets=Total Equity (A: Dec. 2018 )+Total Liabilities (A: Dec. 2018 )
=-78.108+378.475
=300.4

Novelion Therapeutics's Total Assets for the quarter that ended in Mar. 2019 is calculated as

Total Assets=Total Equity (Q: Mar. 2019 )+Total Liabilities (Q: Mar. 2019 )
=-105.27+408.046
=302.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics  (STU:QLTA) Total Assets Explanation

Total Assets is connected with ROA %.

Novelion Therapeutics's annualized ROA % for the quarter that ended in Mar. 2019 is

ROA %=Net Income (Q: Mar. 2019 )/( (Total Assets (Q: Dec. 2018 )+Total Assets (Q: Mar. 2019 ))/ count )
=-112.74/( (300.367+302.776)/ 2 )
=-112.74/301.5715
=-37.38 %

Note: The Net Income data used here is four times the quarterly (Mar. 2019) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Novelion Therapeutics's Asset Turnover for the quarter that ended in Mar. 2019 is

Asset Turnover
=Revenue (Q: Mar. 2019 )/( (Total Assets (Q: Dec. 2018 )+Total Assets (Q: Mar. 2019 ))/ count )
=28.497/( (300.367+302.776)/ 2 )
=28.497/301.5715
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Novelion Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Total Assets
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.